Pharmacovigilance and drug safety current trends and challenges

Year : 2025 | Volume : 12 | Issue : 01 | Page : 19-27
    By

    Mohd. Wasiullah,

  • Piyush Yadav,

  • Shivendra Dubey,

  • Ritu Yadav,

  1. Principal, Dept. of Pharmacy, Prasad Institute Technology, Jaunpur, Uttar Pradesh, India
  2. Professor & Head, Dept. of Pharmaceutical Chemistry, Prasad Institute of Technology, Jaunpur, Uttar Pradesh, India
  3. Lecturer, Dept. of Pharmacy, Prasad Polytechnic, Jaunpur, Uttar Pradesh, India
  4. Scholar, Dept. of Pharmacy, Prasad Polytechnic, Jaunpur, Uttar Pradesh, India

Abstract

Pharmacovigilance and drug safety are critical areas of focus in healthcare, aimed at monitoring the safety and efficacy of pharmaceutical products throughout their lifecycle. This review explores current trends, emerging technologies, and challenges in pharmacovigilance, emphasizing their impact on public health and regulatory practices. With the increasing complexity of global pharmaceutical markets, pharmacovigilance systems are evolving to integrate real-time data analytics, artificial intelligence (AI), and machine learning (ML) to detect adverse drug reactions (ADRs) more efficiently. Despite significant advancements, challenges persist in data standardization, reporting inconsistencies, underreporting of ADRs, and the growing volume of data that needs to be processed. This article highlights key innovations, discusses the barriers hindering optimal drug safety practices, and provides recommendations for enhancing pharmacovigilance frameworks to improve patient safety and regulatory oversight.

Keywords: Pharmacovigilance, drug safety, global pharmacovigilance systems, drug safety challenges, regulatory practices.

[This article belongs to Research & Reviews: A Journal of Drug Formulation, Development and Production ]

How to cite this article:
Mohd. Wasiullah, Piyush Yadav, Shivendra Dubey, Ritu Yadav. Pharmacovigilance and drug safety current trends and challenges. Research & Reviews: A Journal of Drug Formulation, Development and Production. 2025; 12(01):19-27.
How to cite this URL:
Mohd. Wasiullah, Piyush Yadav, Shivendra Dubey, Ritu Yadav. Pharmacovigilance and drug safety current trends and challenges. Research & Reviews: A Journal of Drug Formulation, Development and Production. 2025; 12(01):19-27. Available from: https://journals.stmjournals.com/rrjodfdp/article=2025/view=194768


References

1. Pharmacovigilance (PVG. Pharmacovigilance: ensuring the safe use of medicines [Internet]. Who.int. World Health Organization; 2004 [cited 2024 Dec 27]. Available from: https://www.who.int/publications/i/item/WHOEDM2004.8
2. Härmark L, van Grootheest AC. Pharmacovigilance: methods, recent developments and future perspectives. Eur J Clin Pharmacol. 2008 Aug;64(8):743-52. doi: 10.1007/s00228-008-0475-9.
3. Biswas P, Biswas A. Setting standards for proactive pharmacovigilance in India: The way forward. Indian J Pharmacol. 39(3):p 124-128, May–Jun 2007. | DOI: 10.4103/0253-7613.33431
4. World Health Organization. The Importance of Pharmacovigilance [Internet]. 2002 [cited 2024 Dec 27]. Available from: https://www.who.int/publications/i/item/10665-42493
5. World Health Organization. (‎1973)‎. Handbook of resolutions and decisions of the World Health Assembly and the Executive Board, v. 1: cumulative definitive ed.; v. 2: cumulative definitive ed.; v. 3: 3rd ed.. World Health Organization. https://iris.who.int/handle/10665/79012
6. van Grootheest K, Olsson S, Couper M, de Jong-van den Berg L. Pharmacists’ role in reporting adverse drug reactions in an international perspective. Pharmacoepidemiol Drug Saf. 2004 Jul;13(7):457-64. doi: 10.1002/pds.897.
7. World Health Organization. (‎2000)‎. WHO medicines strategy : framework for action in Essential Drugs and Medicines Policy 2000-2003. World Health Organization. https://iris.who.int/handle/10665/66503
8. Olsson S. The role of the WHO programme on International Drug Monitoring in coordinating worldwide drug safety efforts. Drug Saf. 1998 Jul;19(1):1-10. doi: 10.2165/00002018-199819010-00001.
9. Coulter DM. The New Zealand Intensive Medicines Monitoring Programme. Pharmacoepidemiol Drug Saf. 1998 Mar;7(2):79-90. doi: 10.1002/(SICI)1099-1557(199803/04)7:23.0.CO;2-1
10. Mackay FJ. Post-marketing studies: the work of the Drug Safety Research Unit. Drug Saf. 1998 Nov;19(5):343-53. doi: 10.2165/00002018-199819050-00002.

11. Folb PI, ten Ham M. Drug monitoring in developing countries: A drug regulator’s perspective. Drug Inf J. 1995;29:303–5.
12. Talbot JC, Nilsson BS. Pharmacovigilance in the pharmaceutical industry. Br J Clin Pharmacol. 1998 May;45(5):427-31. doi: 10.1046/j.1365-2125.1998.00713.x.
13. Moore N. The role of the clinical pharmacologist in the management of adverse drug reactions. Drug Saf. 2001 Jan;24(1):1-7. doi: 10.2165/00002018-200124010-00001.
14. Hall M, McCormack P, Arthurs N, Feely J. The spontaneous reporting of adverse drug reactions by nurses. Br J Clin Pharmacol. 1995 Aug;40(2):173-5. doi: 10.1111/j.1365-2125.1995.tb05774.x.
15. Wu HH, Inman WH, Evans DA. Evaluation of spontaneous reports of adverse reactions to drugs. Br Med J. 1972 Sep 23;3(5829):746-9. doi: 10.1136/bmj.3.5829.746.
16. Benefit-Risk Balance for Marketed Drugs: Evaluating Safety Signals [Internet]. COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES. ; 2022 [cited 2024 Dec 27]. Available from: https://cioms.ch/publications/product/benefit-risk-balance-for-marketed-drugs-evaluating-safety-signals/
17. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998 Apr 15;279(15):1200-5. doi: 10.1001/jama.279.15.1200.
18. White TJ, Arakelian A, Rho JP. Counting the costs of drug-related adverse events. Pharmacoeconomics. 1999 May;15(5):445-58. doi: 10.2165/00019053-199915050-00003.
19. Avorn J, Solomon DH. Cultural and economic factors that (mis)shape antibiotic use: the nonpharmacologic basis of therapeutics. Ann Intern Med. 2000 Jul 18;133(2):128-35. doi: 10.7326/0003-4819-133-2-200007180-00012.

20. Ball LK, Evans G, Bostrom A. Risky business: challenges in vaccine risk communication. Pediatrics. 1998 Mar;101(3 Pt 1):453-8. doi: 10.1542/peds.101.3.453.

Regular Issue Subscription Review Article
Volume 12
Issue 01
Received 14/12/2024
Accepted 26/12/2024
Published 20/01/2025
Publication Time 37 Days
Total Visits: 242


My IP

PlumX Metrics